All congress activities

View all AAN AMCP ICNMD CNS WMS MDA EPNS

International congresses, conferences and meetings offer the opportunity to share data and drive discussion that can progress the management of conditions such as Duchenne muscular dystrophy (DMD). Access our content from congresses and society meetings here.

This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows results from a propensity score-matched registry analysis, using data from the STRIDE Registry and CINRG Natural History Study, to determine the effect of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function
This poster, presented at the ICNMD virtual meeting in 2021, shows findings from a registry study investigating the effects of a mutation-specific Duchenne muscular dystrophy (DMD) therapy on pulmonary function in patients with DMD
Year
Therapy area
Congress
Type
Topic

Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and the European Paediatric Neurology Society (EPNS) Congress.

▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.

MED-ALL-DMD-2200043 | March 2022
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
GL-CORP-0207 | June 2021

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.